CSIMarket
 
Biogen Inc   (BIIB)
Other Ticker:  
 
    Sector  Healthcare    Industry Biotechnology & Drugs
   Industry Biotechnology & Drugs
   Sector  Healthcare
 

Biogen Inc 's Customers Performance

BIIB

 
BIIB's Source of Revenues Biogen Inc 's Customers have recorded an increase in their cost of revenue by 17.81 % in the 4 quarter 2020 year on year, sequentially costs of revenue grew by 36.3 %, for the same period Biogen Inc revnue deteriorated by -22.3 % year on year, sequentially revnue fell by -15.51 %.

List of BIIB Customers




Biogen Inc 's Customers have recorded an increase in their cost of revenue by 17.81 % in the 4 quarter 2020 year on year, sequentially costs of revenue grew by 36.3 %, for the same period Biogen Inc revnue deteriorated by -22.3 % year on year, sequentially revnue fell by -15.51 %.

List of BIIB Customers


   
Customers Net Income grew in Q4 by Customers Net margin grew to
16.39 % 3.81 %



Biogen Inc 's Customers, Q4 2020 Revenue Growth By Industry
Customers in Construction Raw Materials Industry      16.12 %
Customers in Accident & Health Insurance Industry      19.43 %
Customers in Life Insurance Industry      13.24 %
Customers in Property & Casualty Insurance Industry      11.44 %
Customers in Healthcare Facilities Industry      1.5 %
Customers in Major Pharmaceutical Preparations Industry      2.19 %
Customers in Pharmacy Services & Retail Drugstore Industry      3.98 %
     
• Customers Valuation • Segment Rev. Growth • Segment Inc. Growth • Customers Mgmt. Effect.


Biogen Inc 's Comment on Sales, Marketing and Customers



We focus our sales and marketing efforts on specialist physicians in private practice or at major medical centers. We use customary pharmaceutical company practices to market our products and to educate physicians, such as sales representatives calling on individual physicians, advertisements, professional symposia, direct mail, public relations and other methods. We provide customer service and other related programs for our products, such as disease and product-specific websites, insurance research services and order, delivery and fulfillment services. We have also established programs in the U.S. which provide qualified uninsured or underinsured patients with marketed products at no or reduced charge, based on specific eligibility criteria. Additional information about our sales, marketing and distribution efforts for our marketed products is set forth below.

AVONEX
We continue to focus our marketing and sales activities on maximizing the potential of AVONEX in the U.S. and the rest of world in the face of increased competition, including from our own products and products of our competitors. The principal markets for AVONEX are the U.S., Germany, France, Italy and the United Kingdom. In the U.S., Canada, Brazil, Argentina, Australia, Japan and most of the major countries of the E.U., we market and sell AVONEX through our own sales forces and marketing groups and distribute AVONEX principally through wholesale distributors of pharmaceutical products, mail order specialty distributors or shipping service providers. In other countries, we sell AVONEX to distribution partners who are then responsible for most marketing and distribution activities.

TYSABRI
The principal markets for TYSABRI are the U.S., the United Kingdom, France, Germany, Italy and Spain. Following the completion of our acquisition of 100% of the rights to TYSABRI from Elan in April 2013, we are solely responsible for the marketing and sale of TYSABRI for MS in the U.S. and the rest of world. We use a combination of our own sales force and marketing group and third party service providers for our marketing and distribution of TYSABRI.
TECFIDERA
The principal market for TECFIDERA is the U.S. and the E.U. In the U.S., E.U., Canada and Australia, we market and sell TECFIDERA through our own sales forces and marketing groups and distribute TECFIDERA principally through wholesale distributors of pharmaceutical products, mail order specialty distributors or shipping service providers.

RITUXAN and GAZYVA
The Roche Group and its sub-licensees market and sell RITUXAN worldwide. In the U.S., we collaborate with Genentech on the development and commercialization of RITUXAN, but Genentech maintains sole responsibility for the U.S. sales and marketing efforts related to RITUXAN. RITUXAN is generally sold to wholesalers, specialty distributors and directly to hospital pharmacies.
Pursuant to our agreement with Genentech, the Roche Group and its sub-licensees will maintain sole responsibility for the development, manufacturing and commercialization of GAZYVA in the U.S.

FAMPYRA
We market and sell FAMPYRA in major markets outside the U.S., such as France, Germany, Spain and Canada, through our own sales forces and marketing groups and distribute FAMPYRA in those markets principally through wholesale distributors of pharmaceutical products. In other countries outside the U.S., we sell FAMPYRA to distribution partners who are then responsible for most marketing and distribution activities. Our commercialization rights do not include the U.S. market.

FUMADERM
FUMADERM is marketed only in Germany, through our own sales force and marketing group.


Biogen Inc 's Comment on Sales, Marketing and Customers


We focus our sales and marketing efforts on specialist physicians in private practice or at major medical centers. We use customary pharmaceutical company practices to market our products and to educate physicians, such as sales representatives calling on individual physicians, advertisements, professional symposia, direct mail, public relations and other methods. We provide customer service and other related programs for our products, such as disease and product-specific websites, insurance research services and order, delivery and fulfillment services. We have also established programs in the U.S. which provide qualified uninsured or underinsured patients with marketed products at no or reduced charge, based on specific eligibility criteria. Additional information about our sales, marketing and distribution efforts for our marketed products is set forth below.

AVONEX
We continue to focus our marketing and sales activities on maximizing the potential of AVONEX in the U.S. and the rest of world in the face of increased competition, including from our own products and products of our competitors. The principal markets for AVONEX are the U.S., Germany, France, Italy and the United Kingdom. In the U.S., Canada, Brazil, Argentina, Australia, Japan and most of the major countries of the E.U., we market and sell AVONEX through our own sales forces and marketing groups and distribute AVONEX principally through wholesale distributors of pharmaceutical products, mail order specialty distributors or shipping service providers. In other countries, we sell AVONEX to distribution partners who are then responsible for most marketing and distribution activities.

TYSABRI
The principal markets for TYSABRI are the U.S., the United Kingdom, France, Germany, Italy and Spain. Following the completion of our acquisition of 100% of the rights to TYSABRI from Elan in April 2013, we are solely responsible for the marketing and sale of TYSABRI for MS in the U.S. and the rest of world. We use a combination of our own sales force and marketing group and third party service providers for our marketing and distribution of TYSABRI.
TECFIDERA
The principal market for TECFIDERA is the U.S. and the E.U. In the U.S., E.U., Canada and Australia, we market and sell TECFIDERA through our own sales forces and marketing groups and distribute TECFIDERA principally through wholesale distributors of pharmaceutical products, mail order specialty distributors or shipping service providers.

RITUXAN and GAZYVA
The Roche Group and its sub-licensees market and sell RITUXAN worldwide. In the U.S., we collaborate with Genentech on the development and commercialization of RITUXAN, but Genentech maintains sole responsibility for the U.S. sales and marketing efforts related to RITUXAN. RITUXAN is generally sold to wholesalers, specialty distributors and directly to hospital pharmacies.
Pursuant to our agreement with Genentech, the Roche Group and its sub-licensees will maintain sole responsibility for the development, manufacturing and commercialization of GAZYVA in the U.S.

FAMPYRA
We market and sell FAMPYRA in major markets outside the U.S., such as France, Germany, Spain and Canada, through our own sales forces and marketing groups and distribute FAMPYRA in those markets principally through wholesale distributors of pharmaceutical products. In other countries outside the U.S., we sell FAMPYRA to distribution partners who are then responsible for most marketing and distribution activities. Our commercialization rights do not include the U.S. market.

FUMADERM
FUMADERM is marketed only in Germany, through our own sales force and marketing group.








BIIB's vs. Customers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)



COMPANY NAME MARKET CAP REVENUES INCOME EMPLOYEES
Biogen Inc 42,891 13,445 4,061 7,550
Aflac Incorporated 36,311 22,147 4,778 9,235
Aetna Inc 70,069 60,705 3,503 48,800
Cigna Corporation 84,891 160,401 8,489 37,200
Humana Inc 53,774 77,155 3,367 57,000
Metlife Inc 52,572 67,842 5,418 66,000
Principal Financial Group inc 16,959 15,024 1,252 14,873
Unitedhealth Group Incorporated 339,346 252,575 17,085 170,000
Wellpoint, Inc. 0 71,427 2,570 0
Hi crush Inc 16 623 -554 0
Tenet Healthcare Corp 6,021 17,640 768 108,000
WALGREEN CO. 0 0 0 251,000
Cvs Health Corporation 94,812 268,706 7,192 217,800
Express Scripts Holding Co. 52,360 100,179 4,607 29,500
The Kroger Co 27,171 128,139 2,306 400,000
WINN-DIXIE STORES, INC. 0 0 0 0
Davita Inc 12,449 11,551 995 57,400
Assurant Inc 8,879 10,095 443 17,600
Anthem Inc 84,422 121,867 4,572 48,200
Investors Heritage Capital Corp 49 63 1 1
Security National Financial Corporation 183 422 53 1,271
American Independence Corp. 0 0 0 268
Centene Corporation 35,647 111,115 1,794 18,200
Cno Financial Group Inc 3,461 3,821 302 3,500
Natur International Corp. 24,295 2 0 150
Triple s Management Corporation 641 3,702 67 3,257
Health Net Inc 0 0 0 50
Molina Healthcare Inc 13,175 19,423 673 21,000
Trupanion Inc 12,562 502 -6 439
Universal American Corp. 0 0 0 961
Wellcare Health Plans inc 17,792 26,983 631 6,900
American National Group Inc 2,576 3,792 469 4,736
Symetra Financial Corporation 0 2,111 210 1,400
Axis Capital Holdings Ltd 4,220 4,842 -120 1,225
Kemper corporation 5,264 5,206 410 5,600
National General Holdings Corp 3,976 5,552 524 4,630
Onebeacon Insurance Group, Ltd. 1,734 1,242 147 1,150
White Mountains Insurance Group ltd 0 1,181 663 2,973
Fresenius Medical Care Ag and Co Kgaa 10,171 20,002 1,608 0
SUBTOTAL 1,075,796 1,596,039 74,216 1,610,319


       
Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

VYNE's Profile

Stock Price

VYNE's Financials

Business Description

Fundamentals

Charts & Quotes

VYNE's News

Suppliers

VYNE's Competitors

Customers & Markets

Economic Indicators

VYNE's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Indices

Sectors & Industries

Financials

Commodities

Currencies

News


At a Glance

Stocks

Economy

Industries

Other

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.  Free Stock Market News Feeds
   Copyright © 2021 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071